Get started
Author

Jianying Zhou

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
2020 · Yi-Long Wu, Ying Cheng, et al. · The Lancet Respiratory Medicine · 271
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
2023 · Ziming Li, Zhengbo Song, et al. · Journal of Thoracic Oncology · 94
PDF
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
2024 · Ziming Li, Xiaomin Dang, et al. · The Lancet Respiratory Medicine · 57
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
2024 · Yongfeng Yu, Qisen Guo, et al. · The Lancet Respiratory Medicine · 39
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2025 · James Chih-Hsin Yang, Mengzhao Wang, et al. · Journal of Clinical Oncology · 35
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
2025 · Caicun Zhou, Ziping Wang, et al. · The Lancet Oncology · 31
Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
2024 · Caicun Zhou, You Lu, et al. · JTO Clinical and Research Reports · 25
PDF
Expert consensus on cancer treatment-related lung injury
2025 · Xinqing Lin, Hui Guo, et al. · Journal of Thoracic Disease · 11
TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer
2022 · Linying Wu, Yuman Yu, et al. · Frontiers in Genetics · 11
PDF
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
2024 · Jin-Ji Yang, Jianying Zhou, et al. · The Lancet Respiratory Medicine · 10
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial
2024 · Shen Zhao, Huaqiang Zhou, et al. · Journal of Thoracic Oncology · 9
PDF
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
2025 · Zhengbo Song, Ziming Li, et al. · European Journal of Cancer · 5
Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.
2012 · Yan Sun, Yuankai Shi, et al. · Journal of Clinical Oncology · 5
ACTL6A accelerates the progression of NSCLC through hippo/YAP signaling axis and TAMs-mediated immune regulation.
2025 · Luyun Cui, Shunjin Zhao, et al. · International Immunopharmacology · 3
Radiofrequency Ablation Versus Thoracoscopic Sublobar Resection for the Treatment of Pulmonary Ground Glass Nodules: A Retrospective Observational Study
2025 · Shunjin Zhao, Lu Shen, et al. · CardioVascular and Interventional Radiology · 3
Immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer patients with preexisting pulmonary emphysema or interstitial lung abnormalities
2025 · Xi Chen, Caijuan Huan, et al. · Lung Cancer · 2
Clinical application of pre-rehabilitation concept on comfort colonoscopy in Chinese elderly patients: a randomised controlled trial
2025 · Lun Zhang, Xiaoling Lv, et al. · BMC Gastroenterology · 2
PDF
Selpercatinib in Chinese patients with RET -fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial
2025 · Shun Lu, Ying Cheng, et al. · Therapeutic Advances in Medical Oncology · 2
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study
2026 · Yongfeng Yu, Qisen Guo, et al. · The Lancet Regional Health - Western Pacific · 1
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
2026 · Jianying Zhou, Yongsheng Wang, et al. · Lung Cancer Targets and Therapy · 1
PDF
β2-adrenergic receptor agonist regulates macrophage polarization via HMGB1 in immune thrombocytopenia
2026 · Qiuyu Guo, Yejun Wu, et al. · Science China Life Sciences
From recognition to action: operationalising frailty assessment in older adults with metabolic dysfunction-associated steatotic liver disease
2026 · Liju Chen, Jianying Zhou, et al. · Digestive and Liver Disease
PDF
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum in Chinese Participants With Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer: Phase 3 LEAP-006 China Extension Study
2026 · Caicun Zhou, Yanqiu Zhao, et al. · JTO Clinical and Research Reports
PDF
Pembrolizumab Plus Chemotherapy for Metastatic Squamous Non‒Small-Cell Lung Cancer: Long-Term Follow-Up of the KEYNOTE-407 China Study
2026 · Jie Hu, Ying Cheng, et al. · JTO Clinical and Research Reports
PDF
Efficacy and safety of deulorlatinib (TGRX-326) in patients with locally advanced or metastatic ALK+ non–small cell lung cancer: A multicenter, open-label, pivotal phase 2 trial.
2026 · Yunpeng Yang, Zhehai Wang, et al. · Journal of Clinical Oncology
Works count: 33
Citation count: 674
H-index: 10
I10-index: 11
Year
Topic
Type